LUPUS NEPHRITIS

This study tests an experimental drug called VIB4920 for people with active lupus nephritis, a serious kidney complication of lupus. About 74 adults will receive either VIB4920 or a placebo, along with standard medications (mycophenolate mofetil and prednisone). The main goal is …

This study compares two ways of giving the drug mycophenolate mofetil to children (ages 8 to under 21) with lupus-related kidney inflammation. One method uses a standard dose based on body size, while the other adjusts the dose based on drug levels in the blood. The goal is to se…

This study tests a one-time cell therapy called rapcabtagene autoleucel for people with active lupus that hasn't improved with standard treatments. About 179 adults will receive the therapy after a short course of chemotherapy to prepare their bodies. The goal is to see if the tr…

This early-stage study tests an experimental drug called IPG11406 in 36 people with lupus nephritis, a kidney complication of lupus. The main goals are to check if the drug is safe and tolerable, and to see early signs it might help kidney function. Participants take the drug by …

This study tests a drug called mosunetuzumab in 30 people with lupus, with or without kidney inflammation. The goal is to see if the drug can put the disease into remission for at least 6 months after treatment ends, without needing ongoing lupus medications (except antimalarials…

This early-stage study tests a one-time treatment made from donor immune cells that are gene-edited to target and destroy faulty immune cells causing disease. It is for 80 adults with severe lupus, scleroderma, or myositis that have not responded to standard therapies. The main g…

This early-stage study tests an experimental drug called UB-VV410 in 21 adults with active lupus (SLE) or lupus kidney disease that hasn't improved with standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs th…

This study tests a drug called obinutuzumab in teens (12-17) and children (5-11) with active lupus nephritis, a serious kidney complication of lupus. The goal is to see if the drug can help the kidneys work better and reduce disease activity. Participants are randomly assigned to…

This early-stage trial tests a personalized cell therapy for adults with severe lupus that hasn't responded to standard treatments. Participants receive a single infusion of their own immune cells, re-engineered to target and destroy the faulty cells driving their disease. The st…

This study tests whether adding the drug iptacopan (LNP023) to standard treatment helps people with active lupus nephritis (kidney inflammation caused by lupus). About 240 adults with biopsy-confirmed lupus nephritis will receive either iptacopan or a placebo alongside their usua…

This early-phase study tests a new treatment called CABA-201 for people with active systemic lupus erythematosus (SLE), including those with kidney inflammation (lupus nephritis). The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that dr…

This study tests whether combining two drugs, belimumab and voclosporin, along with standard treatment, can better control lupus-related kidney inflammation. About 30 adults with active lupus nephritis will take part. The goal is to see if more patients achieve complete kidney re…

This study monitors the safety of the drug LUPKYNIS in 400 people with lupus nephritis who are just starting the medication. Researchers will track side effects and also collect information on how well the drug works in everyday use. The goal is to understand real-world risks and…

This early-stage study tests a new cell therapy called FT819 in people with moderate-to-severe autoimmune diseases like lupus, vasculitis, myositis, and scleroderma. The goal is to see if it is safe and can reduce disease activity by targeting faulty B-cells. About 244 participan…

This study tests a new treatment for autoimmune diseases like lupus and scleroderma. It combines a special immune cell therapy (AD-PluReceptor NK cells) with a targeted drug (tafasitamab) and chemotherapy. The goal is to find a safe dose and see if it can control the disease. Abo…

This study tests a new treatment called obe-cel for people with severe lupus that has not responded to standard therapies and has caused active kidney inflammation (lupus nephritis). Obe-cel is designed to destroy harmful immune cells that drive the disease. The trial will enroll…

This study tests a new treatment called CC-97540, which uses a person's own immune cells (CAR T cells) to target and destroy faulty B cells that drive lupus. It is for people with active systemic lupus erythematosus (SLE) or lupus nephritis who have not improved with steroids and…

This study tests a new treatment called NKX019, which uses specially engineered immune cells (CAR NK cells) to target and calm overactive immune cells that attack the kidneys. It is for people with active lupus nephritis or primary membranous nephropathy who have not responded to…

This 2-year study looks at how well the drug ianalumab works for adults with lupus nephritis, a kidney disease caused by lupus. Some participants who already responded to treatment will stop the drug to see if they stay well, while others will continue or start open-label ianalum…

This study tests whether a drug called obinutuzumab, combined with mycophenolate mofetil (MMF), can control lupus-related kidney disease as well as the standard treatment of oral steroids plus MMF, but without the side effects of long-term steroid use. About 196 people with activ…

This study looks at how well the drug belimumab works in everyday medical practice for adults with active lupus nephritis, a kidney disease caused by lupus. Researchers will follow about 300 people for up to 5 years to see if their kidney function stays stable and if they avoid n…

This study tests a new medicine called ianalumab for people with active lupus nephritis, a kidney problem caused by lupus. About 462 adults will receive either ianalumab or a placebo, added to their usual treatment. The goal is to see if ianalumab can help the kidneys work better…

This study looks at whether doing a repeat kidney biopsy one year after starting treatment for lupus nephritis helps doctors make better treatment decisions. About 206 people with a first episode of lupus nephritis will be randomly assigned to either get the repeat biopsy or not.…

This study is creating a large collection of health information and blood samples from 3,500 people with lupus. Researchers will use this resource to study the causes of lupus, how it affects different people, and why some treatments work better than others. The goal is to speed …